News

TB R&D Weekly Update: Podcast Interview with Armand Van Deun

Dr. Armand Van Deun
Dr. Armand Van Deun

Listen to Armand Van Deun Podcast

Summary: This week’s interview is with Dr. Armand Van Deun who was the recipient of the 2010 Stop TB Partnership-Kochon Foundation prize. Last year, Dr. Van Deun, et al., published an article in the American Journal of Respiratory and Critical Care Medicine entitled “Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis“. In the interview, we discuss this article which presents the results of an observational study in Bangladesh of a treatment for multidrug-resistant TB that incorporates fourth-generation fluoroquinolone combined with other second-line drugs and supplemented by potentially still active first-line drugs.

Dr Van Deun is an international leader on improving laboratory testing for TB. His efforts have had an impact on the quality of work performed by laboratory technologists around the world, resulting in untold thousands of lives saved through diagnosis of TB followed by effective treatment. He pioneered research demonstrating that systematic, random blind checks were critical for ensuring the quality of microscopy results and then traveled the world, educating an entire generation of laboratory leaders, who in turn built the capacity of laboratories in their countries to provide reliable microscopic diagnosis of TB.

A native of Belgium, Dr Van Deun earned his medical degree at the Katholieke Universiteit Leuven in 1978 and later completed specialty training in laboratory medicine at the same institution. Early in his career he spent more than ten years managing TB and leprosy programmes in Tanzania and Rwanda. From 1994 to 1998 he served as Medical Director for the Damien Foundation TB/leprosy control project in Bangladesh, where he initiated a number of research projects, one of which resulted in adoption of revised global guidelines for external quality assessment of acid-fast bacillus smear microscopy.

Since 1999 he has been a researcher at the Institute of Tropical Medicine in Antwerp, Belgium. During this time he has managed the organization and analysis of the annual rounds of proficiency testing of Mycobacterium tuberculosis drug susceptibility tests for the network of Supra-National TB Reference Laboratories worldwide, in the context of the Global TB Drug Resistance Surveillance project of the World Health Organization (WHO) and The Union. Since 2001 he also has consulted on behalf of the Union. In 2008 he was awarded a doctoral degree from the Katholieke Universiteit Leuven.

Additional TB R&D News:

TB Immunotherapy Collaboration Agreement With Stirling Products and Zodiac Capital

Pharmaceutical Giant to Give $5.7 Million Toward Health Programs in Poor Countries

Integrating Neglected Tropical Diseases into AIDS, Tuberculosis, and Malaria Control

Towards zero infections: The UK’s position paper on HIV in the developing world (May 2011)

More News
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...
23 Mar 2022
On March 21st, 2022, the World Health Organization (WHO) updated its guidelines on treatment of non-severe TB disease in children and adolescents. The new guidelines recommend a shorter duration of treatment and reduces the standard of care which is currently 6 months of therapy down to 4 months...